MarketPulse

corabotase

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Ipsen Launches First-in-Class Neuroinhibitor Corabotase, Targeting Aesthetic and Therapeutic Markets

Ipsen launches corabotase, first-in-class recombinant neuroinhibitor, with positive Phase II data showing rapid onset and sustained effect for glabellar lines, advancing broad clinical program.
IPSEYclinical developmentPhase II trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Ipsen's First-in-Class Corabotase Shows Promise in Phase II Wrinkle Trial

Ipsen unveiled Phase II data for corabotase, a first-in-class recombinant neuro-inhibitor, showing rapid onset and sustained benefits for wrinkles at SCALE 2026 symposium.
IPSEYPhase II trialaesthetic medicine